Serum Omentin As A Potential Biomarker For Complex Atypical Hyperplasia and Endometrioid Endometrial Adenocarcinoma
type: CreativeWork
description: Obesity is a significant risk factor for endometrial cancer, the most common gynecologic malignancy in the United States, but much remains unclear about the relationship between obesity-related factors and the development of endometrial cancer. Omentin, a recently discovered adipokine, has been shown to be present in lower levels in patients who are obese and/or insulin resistant. A case-control study was conducted using the serum of 140 women with endometrial cancer and 75 women with endometrial hyperplasia who were matched 1:1 based on body mass index (BMI) and menopausal status to women with no history of endometrial cancer (controls). The concentration of omentin in the patients’ serum was experimentally determined by conducting tests in triplicate on an enzyme-linked immunoadsorbent assay (ELISA) specific to human omentin. The mean serum omentin levels of women with endometrial hyperplasia and endometrial cancer were statistically significantly lower than controls, regardless of BMI. The mechanism that induces this change remains unknown, but these results present exciting promise for omentin’s use as a biomarker and role in understanding the relationship between obesity-related factors and endometrial carcinoma.
abstract: Obesity is a significant risk factor for endometrial cancer, the most common gynecologic malignancy in the United States, but much remains unclear about the relationship between obesity-related factors and the development of endometrial cancer. Omentin, a recently discovered adipokine, has been shown to be present in lower levels in patients who are obese and/or insulin resistant. A case-control study was conducted using the serum of 140 women with endometrial cancer and 75 women with endometrial hyperplasia who were matched 1:1 based on body mass index (BMI) and menopausal status to women with no history of endometrial cancer (controls). The concentration of omentin in the patients’ serum was experimentally determined by conducting tests in triplicate on an enzyme-linked immunoadsorbent assay (ELISA) specific to human omentin. The mean serum omentin levels of women with endometrial hyperplasia and endometrial cancer were statistically significantly lower than controls, regardless of BMI. The mechanism that induces this change remains unknown, but these results present exciting promise for omentin’s use as a biomarker and role in understanding the relationship between obesity-related factors and endometrial carcinoma.
author: Holman, Laura L, MD
keywords: Omentin, Endometrial Cancer, Endometrial Hyperplasia, Female Urogenital Diseases and Pregnancy Complications, Medicine and Health Sciences, Oncology
date published: 2015-05-01T07:00:00Z
date modified: 2026-07-24T05:49:16Z
provider: University of Texas Health Science Center at Houston
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: University of Texas Health Science Center at Houston